Trauma:
Jamas S, Easson D, Ostroff G: "Underivatilized aqueous soluble beta (1,3) glucan, composition and method of making same." U.S. Patent Application 20020032170, March 14, 2002.
Direct Quote: "Beta-glucan was shown to be beneficial in animal models of trauma, wound healing and tumorigenesis."
Browder IW., Williams D., Pretus H., et al; Beneficial Effect of Enhanced Macrophage Function in the Trauma Patients. Ann. Surg.; Vol 211: 605-613. Dept of Surg and Physiol, Tulane U Sch of Med, LA and Istituto Di Chirurgia D’Urgenza, U of Torino, Torino, Italy. 1990.
Direct Quote: “Previous studies have demonstrated that glucan, a beta-1,3-linked glucopyranose polymer, isolated from the inner cell wall of Saccharomyces cerevisiae, is a potent macrophage stimulant and is beneficial in the therapy of experimental bacterial, viral, and fungal diseases. Use of glucan in a murine model of hind-limb crush injury decreased macrophage PGE2 release while stimulating bone marrow proliferation. “
Maurici da Rocha e Silva et al; “Infection Prevention in Patients with Severe Multiple Trauma with the Immunomodulater Beta 1-3 Polyglucose (glucan);” Surgery, Gynecology & Obstetrics; 177:383-388. 1993.
Direct Quote: “The incidence of hospital pneumonia of 55% and sepsis of 35% confirms results of previous studies of patients with multitrauma. Glucan decreased pneumonia and sepsis to a significantly lower level of 9.5%….The mortality rate related to infection decreased from 30.0 to 4.8%. The lower number of instances of pneumonia and sepsis….decreased the period of time in the intensive care and the hospital, with a global reduction of 40% on hospital cost.”
ClinicalImmunity.com © 2008